Search results for "immunotherapy"

showing 10 items of 830 documents

Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells

2020

Papillary renal cell carcinoma (PRCC) is a rare entity in children with no established therapy protocols for advanced diseases. Immunotherapy is emerging as an important therapeutic tool for childhood cancer. Tumor cells can be recognized and killed by conventional and unconventional T cells. Unconventional T cells are able to recognize lipid antigens presented via CD1 molecules independently from major histocompatibility complex, which offers new alternatives for cancer immunotherapies. The nature of those lipids is largely unknown and α-galactosylceramide is currently used as a synthetic model antigen. In this work, we analyzed infiltrating lymphocytes of two pediatric PRCCs using flow cy…

Male0301 basic medicineT-Lymphocytesmedicine.medical_treatmentLymphocyte Activationlipid antigens0302 clinical medicineTumor MicroenvironmentImmunology and AllergyMedicinepediatric papillary renal cell carcinomaChildCells CulturedOriginal Researchmedicine.diagnostic_testbiologyKidney NeoplasmsPhenotypeChild PreschoolCD1DImmunohistochemistrylipids (amino acids peptides and proteins)Signal Transductionlcsh:Immunologic diseases. AllergyAdolescentImmunologyCD1Major histocompatibility complexCD1dPeripheral blood mononuclear cellFlow cytometry03 medical and health sciencesLymphocytes Tumor-InfiltratingAntigenParacrine CommunicationHumansTILsCarcinoma Renal CellCell Proliferationbusiness.industryInfantImmunotherapyLipid Metabolism030104 developmental biologyCase-Control StudiesCancer researchbiology.proteinAntigens CD1dbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC

2020

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately reanalyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negat…

MaleAPOBECCancer ResearchT-Lymphocytesmedicine.medical_treatment610BiologyCohort Studies03 medical and health sciences0302 clinical medicineGene expressionBiomarkers TumormedicineHumansExomeAPOBEC Deaminasestumor inflammationPapillomaviridaeExomeGeneImmune EvasionInflammationSequence Analysis RNASquamous Cell Carcinoma of Head and NeckPapillomavirus InfectionsAPOBECmutational signatureImmunotherapyMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaPhenotypeImmune checkpointddc:Gene Expression Regulation Neoplasticstomatognathic diseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisMutationCancer researchimmune checkpoint inhibitionFemalehead and neck cancerTranscriptome600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitInternational Journal of Cancer
researchProduct

Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observa…

2009

We conducted a large observational study in 193 children and adolescents with allergic rhinitis due to grass or tree pollens to evaluate the safety and tolerability of an ultrarush high-dose sublingual immunotherapy (SLIT) regimen reaching a maintenance dose of 300 index of reactivity within 90 minutes.Children and adolescents aged 5 to 17 years with at least a 1-year medical history of allergic rhinitis with or without mild to moderate asthma due to tree pollens (birch, alder, hazel) or grass pollens (cocksfoot, meadow grass, rye grass, sweet vernal grass, timothy) were recruited. Standardized grass and tree pollen allergen extracts were used for ultrarush titration and subsequent coseason…

MaleAdolescentAdministration SublingualPoaceaeAllergic rhinitisTreesHumansGrasses; Trees; Ultrarush; Sublingual immunotherapy; Children; Safety; Allergic rhinitis; AsthmaGrassesChildChildrenSublingual immunotherapyAntigens Plant; Trees; Immunotherapy; Humans; Asthma; Child; Pollen; Child Preschool; Poaceae; Rhinitis Allergic Seasonal; Seasons; Adolescent; Administration Sublingual; Female; MaleUltrarushRhinitis Allergic SeasonalAntigens PlantAsthmaChild PreschoolPollenFemaleSeasonsImmunotherapySeasonSafetyTreeHuman
researchProduct

TCR-Ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.

2013

Adoptive immunotherapy is a promising therapeutic approach for the treatment of chronic infections and cancer. Thereby, T cells within a certain range of high avidity for their cognate ligand are believed to be most effective. T cell receptor (TCR) transfer experiments indicate that a major part of avidity is hard-wired within the structure of the TCR. Unfortunately, rapid measurement of structural avidity of TCRs is difficult on living T cells. We developed a technology, where dissociation (koff-rate) of truly monomeric peptide major histocompatibility complex (pMHC) molecules bound to surface expressed TCRs can be monitored by real-time microscopy in a highly reliable manner. A first eval…

MaleAdoptive cell transferT cellmedicine.medical_treatmentReceptors Antigen T-CellGenes MHC Class Ichemical and pharmacologic phenomenaStreptamerBiologyCD8-Positive T-LymphocytesMajor histocompatibility complexImmunotherapy AdoptiveArticleMicemedicineCytotoxic T cellAnimalsHumansAvidityCells CulturedT-cell receptorGeneral MedicineImmunotherapyAdoptive Transfermedicine.anatomical_structureImmunologybiology.proteinFemale
researchProduct

Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies

2015

The number of people over 65 is increasing around the world. At present, between 5 and 10% of allergic diseases affect the elderly. In particular, rhinitis is increasing worldwide; the presence of high comorbidity makes the therapy of asthma even more complicated. With reference to dermatological allergies, the dryness of the skin favors the onset of allergic contact and atopic dermatitis, while the senescence of mucous membranes and the impaired secretion of polymeric IgA could be linked to food allergy. Overcoming the problem of adverse drug reaction is limited by the diagnostic difficulty in patients taking multiple drugs. In addition, some drugs, such as β-blockers, angiotensin-converti…

MaleAgingAllergymedicine.medical_specialtyAIT-allergen immunotherapyHealth Services for the AgedImmunologyDrug allergydermatological allergieanaphylaxiDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioelderlyFood allergyHypersensitivitymedicineHumansImmunology and AllergyAsthmaimmunosenescencefood allergybusiness.industryMedicine (all)Atopic dermatitismedicine.diseaseDermatologyPatient ComplianceFemaleallergic rhinitibusinessallergic asthmadrug allergyAnaphylaxisAdverse drug reactionHumanExpert Review of Clinical Immunology
researchProduct

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.

1996

Peptide epitopes derived from differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for MHC-restricted cytotoxic T lymphocytes (CTL). The characterization of multiple CTL-defined antigenic determinants has opened possibilities of development of antigen-targeted vaccines. In the present study, we determined CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase, and gp100/Pmel17 in 3 HLA-A2+ melanoma patients. Then, we assessed the immune responses to synthetic melanoma-associated peptides injected intradermally. After 3 cycles of immunization with peptide alone, we used systemic GM-CSF as an adjuvant du…

MaleCancer ResearchCellular immunitymedicine.medical_treatmentMolecular Sequence Data10050 Institute of Pharmacology and Toxicology610 Medicine & healthchemical and pharmacologic phenomenaActive immunizationEpitopeImmune systemAntigenAdjuvants ImmunologicAntigens NeoplasmmedicineCytotoxic T cellHumans1306 Cancer ResearchHypersensitivity DelayedAmino Acid SequenceMelanomabusiness.industryGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyMiddle AgedImmunohistochemistryNeoplasm ProteinsCTL*OncologyImmunology570 Life sciences; biology2730 OncologyFemaleImmunizationbusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report.

2013

<b><i>Background:</i></b> Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells. In patients with metastatic melanoma, anti-CTLA-4 antibody therapy with ipilimumab achieves durable cancer regression in approximately 10-15% of patients. In the face of complex and sometimes delayed tumor response patterns, prognostic and predictive biomarkers are needed to monitor therapy outcomes and to identify early potential long-term survivors who might also benefit from therapy re-induction. <b><i>Case Report:</i></b> The clinical case of a 49-year-old male patient with metastatic melanoma and u…

MaleCancer ResearchMetastatic melanomamedicine.drug_classmedicine.medical_treatmentStatistics as TopicAntineoplastic AgentsS100 Calcium Binding Protein beta SubunitMonoclonal antibodySensitivity and SpecificitymedicineBiomarkers TumorCytotoxic T cellHumansCTLA-4 AntigenMelanomabusiness.industryMelanomaAntibodies MonoclonalReproducibility of ResultsHematologyImmunotherapyMiddle Agedmedicine.diseaseIpilimumabBlockadeTreatment OutcomeOncologyCTLA-4Cancer researchBiomarker (medicine)businessOnkologie
researchProduct

Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach.

2009

In this paper, we consider the role of the genetics of inflammation in the pathophysiology of prostate cancer (PCa). This paper is not an extensive review of the literature, rather it is an expert opinion based on data from authors' laboratories on age-related diseases and inflammation. The aim is the detection of a risk profile that potentially allows both the early identification of individuals at risk for disease and the possible discovery of potential targets for medication. In fact, a major goal of clinical research is to improve early detection of age-related diseases, cancer included, by developing tools to move diagnosis backward in disease temporal course, i.e., before the clinical…

MaleCancer ResearchPathologymedicine.medical_specialtyAgingpharmacogenomicmedicine.medical_treatmentImmunologyGenomicsDiseaseBioinformaticsProstate cancerlongevitySettore MED/05 - Patologia ClinicaImmunology and AllergyMedicineHumansGenetic Predisposition to DiseaseSettore MED/04 - Patologia GeneraleInflammationPolymorphism Geneticbusiness.industryCancerProstatic NeoplasmsImmunotherapyprostate cancermedicine.diseaseClinical researchOncologyageingPharmacogeneticsPharmacogenomicsgeneticInflammation MediatorsbusinessPharmacogeneticsCancer immunology, immunotherapy : CII
researchProduct

Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.

2013

Intra-tumor injection of immunotherapeutic agents is often the most effective, likely because of concomitant modification of tumor microenvironment. We tested an immunotherapeutic regimen consisting of CpG oligonucleotides and of adenovirus-mediated gene delivery of CCL16 chemokine directly into orthotopically implanted prostate tumors by ultrasound-guided injection, followed by systemic administration of an anti-IL-10R antibody. This combination treatment induced rapid stromal rearrangement, characterized by massive leukocyte infiltration and large areas of necrosis, a scenario that eventually led to complete tumor rejection and systemic immunity in 75 % of the treated mice. In vivo T lymp…

MaleCancer ResearchPathologymedicine.medical_specialtyStromal cellmedicine.medical_treatmentImmunologyFluorescent Antibody TechniqueGene deliveryCD8-Positive T-LymphocytesInjections Intralesionalprostate cancer;immunotherapyAdenoviridaeImmunoenzyme TechniquesProstate cancerMiceTumor Cells CulturedImmunology and AllergyMedicineAnimalsHumansCell ProliferationUltrasonographyTumor microenvironmentbusiness.industryAntibodies MonoclonalProstatic NeoplasmsImmunotherapyT lymphocyteGenetic Therapyprostate cancermedicine.diseaseCombined Modality TherapyInterleukin-10Mice Inbred C57BLOncologyOligodeoxyribonucleotidesChemokines CCSystemic administrationImmunotherapybusinessCD8Cancer immunology, immunotherapy : CII
researchProduct

Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.

2017

IF 2.755; International audience; To assess the risk of second primary malignancy (SPM) in patients with gastric mucosa-associated lymphoid tissue (MALT) Lymphoma (GML), we included 175 patients with GML in the present study. The incidence of SPM in the general population, used for reference, was determined from the French network of cancer registries. During the 1442.9 patient-years of follow-up, 29 patients were diagnosed with incident SPM, including five patients diagnosed with gastric cancer (20.1/1000 patient-years). An increased incidence of SPM was observed in patients with GML (standardized incidence ratios [SIR]: 1.71 [1.14-2.45]) compared to the general French population especiall…

MaleCancer ResearchPathologymedicine.medical_treatmentGastroenterology[ SDV.CAN ] Life Sciences [q-bio]/CancerMALT0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy Protocolsalkylating agentsAged 80 and overeducation.field_of_studyrituximab plus chlorambucilbiologyIncidence (epidemiology)Incidencet(11.18) translocationNeoplasms Second PrimaryHematologyMiddle Aged3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleImmunotherapymedicine.medical_specialtyPopulation[SDV.CAN]Life Sciences [q-bio]/CancerMalignancy03 medical and health sciencesStomach NeoplasmsInternal medicinemedicineGastric mucosaHumanseducationAgedNeoplasm StagingRetrospective StudiesChemotherapyRadiotherapybusiness.industryfungiCancerLymphoma B-Cell Marginal ZoneHelicobacter pylorimedicine.diseasebiology.organism_classificationLymphomaOriginal Article: ClinicalbusinessFollow-Up Studies
researchProduct